PNC:NYSE
PNC Financial Services Group, Inc. (The)
Data as of 2026-03-10 - not real-time
$205.34
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
PNC is trading at $205.34, notably below its 20‑day ($223.19) and 50‑day ($221.61) simple moving averages, yet it remains above the 200‑day SMA ($199.09), indicating a longer‑term bullish backdrop. The RSI of 32 signals oversold conditions, while the MACD remains in a bearish divergence, suggesting short‑term downside pressure may be limited. Fundamentally, the bank posted record Q4 2025 revenue with an 8% year‑over‑year increase, net income of $2.0 B and EPS of $4.88, and operating leverage improved by 5%, reinforcing its earnings momentum. Valuation appears mixed: a PE of 12.38 is well below the industry average of 17.38, supporting a value case, yet the DCF‑derived fair value of $43.54 is far beneath the current price, flagging potential overvaluation. The dividend yield of 3.3% with a 39.8% payout ratio is comfortably sustainable given the $14.5 B cash position.
Analyst sentiment is upbeat – Keefe Bruyette raised the price target to $247 and the consensus recommendation is a “Buy” with a median target of $251. The stock’s beta of ~0.95 and a 30‑day volatility of ~30% signal market‑aligned risk, while rising volume underscores growing investor interest. With solid cash generation, a disciplined share‑repurchase program, and inclusion on dividend‑contender lists, PNC offers a compelling blend of income and growth, though short‑term technical weakness and valuation concerns warrant a measured approach.
Analyst sentiment is upbeat – Keefe Bruyette raised the price target to $247 and the consensus recommendation is a “Buy” with a median target of $251. The stock’s beta of ~0.95 and a 30‑day volatility of ~30% signal market‑aligned risk, while rising volume underscores growing investor interest. With solid cash generation, a disciplined share‑repurchase program, and inclusion on dividend‑contender lists, PNC offers a compelling blend of income and growth, though short‑term technical weakness and valuation concerns warrant a measured approach.
Trading Recommendations
Short Term
< 1 yearhold
Conviction: 6/10
Key Factors
- RSI indicating oversold conditions
- Price near key support at $198.04
- Bearish MACD suggesting limited upside
Medium Term
1–3 yearsbuy
Conviction: 8/10
Key Factors
- Record revenue and EPS beat
- Analyst price target lift to $247
- Sustainable 3.3% dividend yield
Long Term
> 3 yearshold
Conviction: 7/10
Key Factors
- Strong cash position and dividend sustainability
- Long‑term earnings growth from rate tailwinds
- Potential overvaluation relative to DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth9.60%
Profit Margin31.08%
P/E Ratio12.4
ROE12.16%
ROA1.23%
P/B Ratio1.5
Op. Cash Flow$4.4B
Industry P/E17.4
Technical Analysis
TrendBullish
RSI32.2
Support$198.04
Resistance$243.65
MA 20$223.19
MA 50$221.61
MA 200$199.09
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$43.54
Target Price$251.90
Upside/Downside22.68%
GradeOvervalued
TypeBlend
Dividend Yield3.30%
Risk Assessment
Beta0.95
Volatility29.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.